313 related articles for article (PubMed ID: 19808028)
1. Recombinant pro-apoptotic Mycobacterium tuberculosis generates CD8+ T cell responses against human immunodeficiency virus type 1 Env and M. tuberculosis in neonatal mice.
Ranganathan UD; Larsen MH; Kim J; Porcelli SA; Jacobs WR; Fennelly GJ
Vaccine; 2009 Dec; 28(1):152-61. PubMed ID: 19808028
[TBL] [Abstract][Full Text] [Related]
2. Priming with a recombinant pantothenate auxotroph of Mycobacterium bovis BCG and boosting with MVA elicits HIV-1 Gag specific CD8+ T cells.
Chapman R; Shephard E; Stutz H; Douglass N; Sambandamurthy V; Garcia I; Ryffel B; Jacobs W; Williamson AL
PLoS One; 2012; 7(3):e32769. PubMed ID: 22479338
[TBL] [Abstract][Full Text] [Related]
3. CD8 T Cells Show Protection against Highly Pathogenic Simian Immunodeficiency Virus (SIV) after Vaccination with SIV Gene-Expressing BCG Prime and Vaccinia Virus/Sendai Virus Vector Boosts.
Kato S; Shida H; Okamura T; Zhang X; Miura T; Mukai T; Inoue M; Shu T; Naruse TK; Kimura A; Yasutomi Y; Matsuo K
J Virol; 2021 Jan; 95(4):. PubMed ID: 33087465
[TBL] [Abstract][Full Text] [Related]
4. Development of a Live Recombinant BCG Expressing Human Immunodeficiency Virus Type 1 (HIV-1) Gag Using a pMyong2 Vector System: Potential Use As a Novel HIV-1 Vaccine.
Kim BJ; Kim BR; Kook YH; Kim BJ
Front Immunol; 2018; 9():643. PubMed ID: 29636755
[TBL] [Abstract][Full Text] [Related]
5. HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Primates.
García-Arriaza J; Perdiguero B; Heeney JL; Seaman MS; Montefiori DC; Yates NL; Tomaras GD; Ferrari G; Foulds KE; Roederer M; Self SG; Borate B; Gottardo R; Phogat S; Tartaglia J; Barnett SW; Burke B; Cristillo AD; Weiss DE; Lee C; Kibler KV; Jacobs BL; Wagner R; Ding S; Pantaleo G; Esteban M
J Virol; 2017 May; 91(9):. PubMed ID: 28179536
[TBL] [Abstract][Full Text] [Related]
6. Vaccine platform for prevention of tuberculosis and mother-to-child transmission of human immunodeficiency virus type 1 through breastfeeding.
Im EJ; Saubi N; Virgili G; Sander C; Teoh D; Gatell JM; McShane H; Joseph J; Hanke T
J Virol; 2007 Sep; 81(17):9408-18. PubMed ID: 17596303
[TBL] [Abstract][Full Text] [Related]
7. The improved antibody response against HIV-1 after a vaccination based on intrastructural help is complemented by functional CD8+ T cell responses.
Storcksdieck genannt Bonsmann M; Niezold T; Hannaman D; Überla K; Tenbusch M
Vaccine; 2016 Apr; 34(15):1744-51. PubMed ID: 26945099
[TBL] [Abstract][Full Text] [Related]
8. Clearance of HIV type 1 envelope recombinant sendai virus depends on CD4+ T cells and interferon-gamma but not B cells, CD8+ T cells, or perforin.
Surman SL; Brown SA; Jones BG; Woodland DL; Hurwitz JL
AIDS Res Hum Retroviruses; 2010 Jul; 26(7):783-93. PubMed ID: 20623995
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of humoral, mucosal, and cellular immune responses following co-immunization of HIV-1 Gag and Env proteins expressed by Newcastle disease virus.
Khattar SK; Palaniyandi S; Samal S; LaBranche CC; Montefiori DC; Zhu X; Samal SK
Hum Vaccin Immunother; 2015; 11(2):504-15. PubMed ID: 25695657
[TBL] [Abstract][Full Text] [Related]
10. Preclinical development of BCG.HIVA
Mahant A; Saubi N; Eto Y; Guitart N; Gatell JM; Hanke T; Joseph J
Hum Vaccin Immunother; 2017 Aug; 13(8):1798-1810. PubMed ID: 28426273
[TBL] [Abstract][Full Text] [Related]
11. Virological and immunological characterization of novel NYVAC-based HIV/AIDS vaccine candidates expressing clade C trimeric soluble gp140(ZM96) and Gag(ZM96)-Pol-Nef(CN54) as virus-like particles.
Perdiguero B; Gómez CE; Cepeda V; Sánchez-Sampedro L; García-Arriaza J; Mejías-Pérez E; Jiménez V; Sánchez C; Sorzano CÓ; Oliveros JC; Delaloye J; Roger T; Calandra T; Asbach B; Wagner R; Kibler KV; Jacobs BL; Pantaleo G; Esteban M
J Virol; 2015 Jan; 89(2):970-88. PubMed ID: 25355891
[TBL] [Abstract][Full Text] [Related]
12. Prime-boost immunization of codon optimized HIV-1 CRF01_AE Gag in BCG with recombinant vaccinia virus elicits MHC class I and II immune responses in mice.
Promkhatkaew D; Pinyosukhee N; Thongdeejaroen W; Teeka J; Wutthinantiwong P; Leangaramgul P; Sawanpanyalert P; Warachit P
Immunol Invest; 2009; 38(8):762-79. PubMed ID: 19860587
[TBL] [Abstract][Full Text] [Related]
13. Novel recombinant Mycobacterium bovis BCG, ovine atadenovirus, and modified vaccinia virus Ankara vaccines combine to induce robust human immunodeficiency virus-specific CD4 and CD8 T-cell responses in rhesus macaques.
Rosario M; Hopkins R; Fulkerson J; Borthwick N; Quigley MF; Joseph J; Douek DC; Greenaway HY; Venturi V; Gostick E; Price DA; Both GW; Sadoff JC; Hanke T
J Virol; 2010 Jun; 84(12):5898-908. PubMed ID: 20375158
[TBL] [Abstract][Full Text] [Related]
14. A lipidated bi-epitope vaccine comprising of MHC-I and MHC-II binder peptides elicits protective CD4 T cell and CD8 T cell immunity against Mycobacterium tuberculosis.
Rai PK; Chodisetti SB; Maurya SK; Nadeem S; Zeng W; Janmeja AK; Jackson DC; Agrewala JN
J Transl Med; 2018 Oct; 16(1):279. PubMed ID: 30305097
[TBL] [Abstract][Full Text] [Related]
15. HIV-1 Subtype C Mosaic Gag Expressed by BCG and MVA Elicits Persistent Effector T Cell Responses in a Prime-Boost Regimen in Mice.
Jongwe TI; Chapman R; Douglass N; Chetty S; Chege G; Williamson AL
PLoS One; 2016; 11(7):e0159141. PubMed ID: 27427967
[TBL] [Abstract][Full Text] [Related]
16. Pre-clinical development of BCG.HIVA(CAT), an antibiotic-free selection strain, for HIV-TB pediatric vaccine vectored by lysine auxotroph of BCG.
Saubi N; Mbewe-Mvula A; Gea-Mallorqui E; Rosario M; Gatell JM; Hanke T; Joseph J
PLoS One; 2012; 7(8):e42559. PubMed ID: 22927933
[TBL] [Abstract][Full Text] [Related]
17. Robust immunity to an auxotrophic Mycobacterium bovis BCG-VLP prime-boost HIV vaccine candidate in a nonhuman primate model.
Chege GK; Burgers WA; Stutz H; Meyers AE; Chapman R; Kiravu A; Bunjun R; Shephard EG; Jacobs WR; Rybicki EP; Williamson AL
J Virol; 2013 May; 87(9):5151-60. PubMed ID: 23449790
[TBL] [Abstract][Full Text] [Related]
18. Mucosal Immunization with Newcastle Disease Virus Vector Coexpressing HIV-1 Env and Gag Proteins Elicits Potent Serum, Mucosal, and Cellular Immune Responses That Protect against Vaccinia Virus Env and Gag Challenges.
Khattar SK; Manoharan V; Bhattarai B; LaBranche CC; Montefiori DC; Samal SK
mBio; 2015 Jul; 6(4):e01005. PubMed ID: 26199332
[TBL] [Abstract][Full Text] [Related]
19. Superiority in Rhesus Macaques of Targeting HIV-1 Env gp140 to CD40 versus LOX-1 in Combination with Replication-Competent NYVAC-KC for Induction of Env-Specific Antibody and T Cell Responses.
Zurawski G; Shen X; Zurawski S; Tomaras GD; Montefiori DC; Roederer M; Ferrari G; Lacabaratz C; Klucar P; Wang Z; Foulds KE; Kao SF; Yu X; Sato A; Yates NL; LaBranche C; Stanfield-Oakley S; Kibler K; Jacobs B; Salazar A; Self S; Fulp W; Gottardo R; Galmin L; Weiss D; Cristillo A; Pantaleo G; Levy Y
J Virol; 2017 May; 91(9):. PubMed ID: 28202751
[TBL] [Abstract][Full Text] [Related]
20. A Novel MVA-Based HIV Vaccine Candidate (MVA-gp145-GPN) Co-Expressing Clade C Membrane-Bound Trimeric gp145 Env and Gag-Induced Virus-Like Particles (VLPs) Triggered Broad and Multifunctional HIV-1-Specific T Cell and Antibody Responses.
Perdiguero B; Sánchez-Corzo C; Sorzano COS; Saiz L; Mediavilla P; Esteban M; Gómez CE
Viruses; 2019 Feb; 11(2):. PubMed ID: 30781504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
